Maximally Tolerated or Suboptimal Therapy? Clinical Perspectives on Rechallenging RAASi Therapy

Maximally Tolerated or Suboptimal Therapy? Clinical Perspectives on Rechallenging RAASi Therapy is organized by Medtelligence.

Released: 09/09/2022
Valid until: 09/09/2023

Overview:
In heart failure, the use of MRAs is often delayed despite being a crucial part of medical therapy. The evidence is clear that clinical inertia and the suboptimal use of these therapies leads to poorer outcomes for our patients. Join Dr. Ileana Piña and Dr. Patrick Rossignol as they discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for our patients with heart failure.

Learning Objectives:
After participating in this educational activity, participants should be better able to:
• Understand the current gaps in care for patients with HFrEF that contribute to suboptimal dosing
• Discuss an evidence-based approach to dose modifications of RAASi therapy in patients with HFrEF and kidney dysfunction
• Evaluate approaches to rechallenging RAASi therapy utilizing potassium binders in the treatment of HFrEF

Additional Details Will Be Posted as Soon as Information is Available.